Similarly, a BA-deletion in the genome of a patient with breast adenocarcinoma correlated with 26-fold overexpression of SLC22A2 compared with the rest of the patients with breast cancer (Fig. 4e). This evidence concerns the gene CFB and breast adenocarcinoma.